Ming-Chu Hsu, Ph.D.
Founder, President, CEO and Chairman of the Board
Dr. Hsu founded TaiGen in 2001, after successfully building the Biotechnology and Pharmaceutical Research Division of the National Health Research Institutes in Taiwan as its founding director. She was also the leader of the Biotechnology/Pharmaceutical Research Program at the National Science and Technology Program in Taiwan, bringing together 62 academic laboratories to conduct mission-oriented research. Before her return to Taiwan in 1998, Dr. Hsu held the position of Research Director, Oncology and Virology at Hoffmann-La Roche, USA, for over 10 years. Prior to that, Dr. Hsu was an assistant professor at Rockefeller University, New York, and a Research Fellow at the California Institute of Technology at Stanford University. Dr. Hsu obtained her Ph.D. degree in biochemistry from the University of Illinois, Urbana-Champaign. Dr. Hsu has extensive experience in establishing both world-class drug discovery teams and clinical development programs.

Max Chan
Chief Financial Officer, Finance & Administration
Mr. Chan joined TaiGen Biotechnology in October 2010 as CFO, responsible for overall finance and administration. Prior to joining TaiGen, Mr. Chan served as CFO of Himax Technologies, a Nasdaq-listed company, from 2004 to 2010. Prior to joining Himax, he was treasury manager of Intel Capital, the strategic investment division of Intel Corporation in Taiwan from 2000 to 2004, senior associate of Credit Suisse First Boston Asia International (Cayman) Limited, Taiwan Branch in 2000 and a manager of the Overseas Direct Investment Department of China Development Industrial Bank from 1992 to 2000. Mr. Chan holds a B.S. degree in civil engineering and an M.B.A. degree in finance from National Taiwan University and an M.S. degree in business administration from the University of Illinois at Urbana-Champaign.

Peter Tsao, PhD, MBA
Vice President of Business Development
Dr. Tsao joined TaiGen Biotechnology in August 2011 as Vice President, Business Development, responsible for overall business development activities. Prior to joining TaiGen, Dr. Tsao was Senior Director, Business Development at Repros Therapeutics where he was responsible for all global business development activities. Prior to Repros, he was Director, Business Development with Mitsubishi Tanabe Pharma and its predecessor, Tanabe Seiyaku, heading up the business development office in San Diego, USA. He joined Tanabe Seiyaku in 1996 as a research scientist in drug discovery and transitioned to licensing and business development after receiving his M.B.A. from Temple University (Tokyo Campus). Dr. Tsao received his B.S. and Ph.D. in pharmacology from the University of Toronto.

Philip Kuo-Lung Huang
Vice President, Product Development & Marketing General Manager, TaiGen Beijing Office
Prior to joining TaiGen in 2004, Mr. Huang was with Takeda Pharmaceutical for six years and held a number of positions including Sales and Marketing Director in Beijing, Asia Marketing Strategic Manager in Osaka, and Sales and Marketing Director in Taiwan. Before that, Mr. Huang was with Sandoz (Novartis) Taiwan and MSD Taiwan for 15 years and held various positions, most recently as the Director of Business Development and Product Management. Mr. Huang graduated from Taipei Medical College and is a licensed pharmacist.


Chi-Hsin Richard King, Ph.D.
Senior Vice President, Research
Dr. King has over 20 years of medicinal chemistry and chemical development experience in the pharmaceutical industry. Prior to joining TaiGen in July, 2005, Dr. King was with Hoechst Marion Roussel as Section Head of Chemical Development. He was the inventor of alternative synthetic routes of Fexofenadine HCl, the active ingredient of a world leading nonsedating antihistamine AllegraTM and its enantiomers. Dr. King then moved to Union Chemical Laboratories, a division of Taiwan's Industrial Technology Research Institute (ITRI) in 1996 where he served as the Director, leading a multi-disciplinary pharmaceutical development program. In 1997 Dr. King joined Albany Molecular Research and became the Director of Medicinal Chemistry, in charge of chemical development and discovery chemistry with an emphasis on directing and implementing multiple client projects. Dr. King obtained his Ph.D. in organic chemistry from University of Utah.

Ada Kung, Ph.D., DABT, MBA
Senior Vice President, Preclinical Development
Dr. Ada Kung is the Senior Vice President of Preclinical Development of Taigen Biotechnology in Taiwan. Previously she was the president for an international consulting firm specialized in drug development for small molecules, protein drugs and botanical products. Prior to this she was the co-founder of Bridge Pharmaceuticals and later assumed the role of Chief Technical Officer of the company and General Manager of the Laboratory. Dr. Kung was instrumental in establishing from ground-up one of the first Western standard GLP complied and AAALAC accredited state-of-the-art preclinical testing facilities in Beijing, China.

Dr. Kung is a career pharmacologist and established many DMPK and animal efficacy models. She is an American Board of Toxicology certified toxicologist. Dr. Kung’s career has expanded to regulatory affairs and quality systems. She was responsible for filing many IND’s with US FDA and other international regulatory agencies. Dr. Kung has held a variety of top management positions in the pharmaceutical and biotech industries.

Yi-Jong Lin, Ph.D., DABT
Vice President, Regulatory Affairs
Dr. Lin joined TaiGen in 2008, after holding senior positions at Eisai Medical Research Inc., Otsuka Maryland Research Institute, Colgate-Palmolive Company and most recently at Amidabalin LLC, where he was President and Senior Partner. With more than 27 years experience in the new drug development, Dr. Lin has been responsible for a number of original IND / CTA preparations and submissions, as well as supporting NDA and MAA submissions to regulatory agencies worldwide, including the US FDA, Health Canada, MHLW and EMEA. After receiving his B.S. in Pharmacy from Kaohsiung Medical University, Taiwan, Dr. Lin went to Japan as a Rotary International Fellowship scholar and earned his M.S. and Ph.D. degrees in Pharmaceuticals at the University of Tokyo. He is a registered Pharmacist both in Taiwan and Japan.

David Chung, M.D.
Vice President of Clinical Operation
Dr. Chung first joined TaiGen in 2003, and most recently has held a number of Clinical Research Physician, Medical Director and Assistant Medical Director positions at major pharmaceutical companies' operations in Taiwan and Hong Kong, such as Wyeth, MSD, and Eli Lilly and Company. Prior to this, Dr. Chung was the Director, Internal Medicine, Schmidt Group Practice Clinic, and the Attending Physician, Gastroenterology and Hepatology, CGMH, Keelung, Taiwan. He received his Doctor of Medicine degree in 1993 from the School of Medicine, Chang Gung University, Taiwan.


Joe Hsueh
Vice President of Corporate Operations
Having joined TaiGen at its founding, Joe has been involved in many aspects of the company, including fund-raising, and is currently responsible for managing overall corporate operations. Prior to joining TaiGen, Joe worked at biotech investment firm Cheng Xin Venture Capital as an investment manager. At Cheng Xin, he conducted start-up fund-raising for a company dedicating to protein drug discovery and development, and led a private placement for a bio-chip company based in US. Joe got his MBA degree from Fairleigh Dickinson University (FDU), New Jersey in 1997, has a bachelor degree in microbiology from Soochow University in Taiwan.



Top